DB
David Berg
Harvard University
Research areas: Medicine · Cardiology and Cardiovascular Medicine · Mechanical Circulatory Support Devices · Heart Failure Treatment and Management · Acute Myocardial Infarction Research
0000-0002-0366-5492
Employment
-
Harvard University Physician-researcher
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (87)
- Variation in Vasoactive Treatment Selection for Cardiogenic Shock: Insights From the Critical Care Cardiology Trials Network (CCCTN) Save
- Dapagliflozin in Patients With Heart Failure Across the Care Spectrum Save
- Beyond Siloed Care: The Promise and Challenge of Cardiovascular-Kidney-Metabolic Syndrome Save
- Pressure-Adjusted Heart Rate by Echocardiography and Mortality in the Cardiac Intensive Care Unit Save
- Growth Differentiation Factor-15 and the Effect of Dapagliflozin in Heart Failure: Insights From the DAPA-HF Trial Save
- A Road Map to Understanding Cardiovascular Disease in Diabetes: From the AHA Strategically Focused Research Network in Cardiometabolic Health and Type 2 Diabetes Save
- Time for Precision Medicine in Atrial Fibrillation Management? Not So Fast. Save
- Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure Save
- Contemporary Practice Patterns of Vasoactive Use in Cardiogenic Shock in the American Heart Association Cardiogenic Shock Registry Save
- Prehospital Prediction of Cardiogenic Shock Among Patients With ST‐Segment–Elevation Myocardial Infarction: The EARLY SHOCK Score Save
- Medical Intensive Care Unit Overflow Into the Cardiac Intensive Care Unit Save
- A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular Risk Save
- Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation Save
- Interleukin-6 in Heart Failure With Reduced Ejection Fraction and the Effect of Dapagliflozin Save
- Rationale and Design of the Dapagliflozin Effect on Cardiovascular Events in Acute Heart Failure (DAPA ACT HF)-TIMI 68 Trial Save
- Biomarker-Based Model for Prediction of Ischemic Stroke in Patients With Atrial Fibrillation Save
- Early Evolution of SCAI Shock Stage and In-Hospital Mortality in the Cardiovascular Intensive Care Unit Population: From the Critical Care Cardiology Trials Network (CCCTN) Save
- Mixed Cardiogenic-Vasodilatory Shock Save
- Using Selection Criteria From the DanGer Shock Trial in a Contemporary Cohort With Cardiogenic Shock Save
- Epidemiology of cardiogenic shock using the Shock Academic Research Consortium (SHARC) consensus definitions Save